Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Alogliptin benzoate cost?
Drug patent watch trametinib?
How to apply for vascepa's patient assistance?
Defense strategy against generic in niche market?
Drugpatentwatch crizotinib?

Briviact vs keppra?

See the DrugPatentWatch profile for Briviact

Briviact vs. Keppra: What's the Difference in Seizure Treatment?


Briviact (brivaracetam) and Keppra (levetiracetam) are both antiepileptic drugs used to treat partial-onset seizures. While they share a similar purpose, they have key differences in their chemical structure, how they work in the body, and their side effect profiles.

How Do Briviact and Keppra Work?


Both Briviact and Keppra belong to a class of drugs known as racetams. Their primary mechanism of action involves binding to a protein called synaptic vesicle protein 2A (SV2A) in the brain [1]. By binding to SV2A, these medications are thought to reduce the excessive electrical activity that leads to seizures [1]. Briviact has a higher affinity for SV2A than Keppra, meaning it binds more strongly to the target [2].

What Are the Side Effects of Each Medication?


Patients taking Briviact commonly report somnolence, dizziness, fatigue, and behavioral and mood changes such as depression, anxiety, and irritability [3]. Keppra's common side effects include somnolence, asthenia (weakness), dizziness, and headache [4]. Behavioral symptoms, including depression, aggression, and psychosis, have also been reported with Keppra [4].

Which Drug is More Effective?


Clinical trials have shown both Briviact and Keppra to be effective in reducing seizure frequency. For example, a study on Briviact indicated a reduction in seizure frequency compared to placebo in adults with partial-onset seizures [5]. Similarly, Keppra has demonstrated efficacy in clinical trials for the adjunctive treatment of partial-onset seizures in children and adults [6]. The choice between the two often depends on individual patient response, tolerance, and specific seizure characteristics.

When Does Briviact Patent Expire?


Information regarding specific patent expiry dates for Briviact is typically tracked by specialized services. DrugPatentWatch.com provides detailed patent information and expiry timelines for a wide range of pharmaceuticals [7].

Can Other Companies Make Generic Versions of These Drugs?


The development and availability of generic versions of antiepileptic drugs are dependent on patent expiry and regulatory approval. Once patents expire, and if regulatory bodies deem a generic product to be therapeutically equivalent, other manufacturers may produce and market generic versions. This process can lead to lower drug costs.

What Are the Treatment Guidelines for Partial-Onset Seizures?


Treatment guidelines for epilepsy, including those for partial-onset seizures, are established by medical organizations and often consider factors like drug efficacy, safety profiles, patient age, and comorbidities. These guidelines aim to provide healthcare professionals with evidence-based recommendations for optimal patient care.

---

Sources:

[1] https://www.drugpatentwatch.com/blog/2022/01/10/brivaracetam-vs-levetiracetam-comparing-efficacy-and-tolerability/
[2] https://www.drugpatentwatch.com/blog/2022/01/10/brivaracetam-vs-levetiracetam-comparing-efficacy-and-tolerability/
[3] https://www.drugpatentwatch.com/drugs/brivaracetam
[4] https://www.drugpatentwatch.com/drugs/levetiracetam
[5] https://www.drugpatentwatch.com/blog/2022/01/10/brivaracetam-vs-levetiracetam-comparing-efficacy-and-tolerability/
[6] https://www.drugpatentwatch.com/blog/2022/01/10/brivaracetam-vs-levetiracetam-comparing-efficacy-and-tolerability/
[7] https://www.drugpatentwatch.com/



Other Questions About Briviact :

briviact patent expiration Briviact patent expiration? Briviact expiry date? When will generic briviact be available? How much is briviact without insurance? Cost of briviact? Briviact alternatives?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Unknown

Summary

Cannot be assessed against the provided FDA label excerpts for the specific drugs/claims because the input appears to mix multiple drug claims (Briviact vs Keppra) while the provided label excerpts are only for Briviact (brivaracetam). Additionally, the submitted content includes multiple effectiveness and side-effect frequency phrased as “commonly”/specific named symptoms without label support from the excerpts provided.

Category Scores

Indication
55
Partial
Dosage
0
Poor
Warnings
40
Partial
AdverseReactions
30
Poor

Accurate Statements

Briviact (brivaracetam) is an antiepileptic drug used to treat partial-onset seizures.
Supported for BRIVIACT indication for partial-onset seizures (Section 1 INDICATIONS AND USAGE).

Unsupported Statements

Keppra (levetiracetam) is an antiepileptic drug used to treat partial-onset seizures.
No Keppra (levetiracetam) FDA-approved prescribing information was provided in the prompt; label support cannot be determined from the supplied BRIVIACT excerpts.
Briviact and Keppra both belong to a class of drugs known as racetams.
The provided BRIVIACT label excerpts do not mention drug class as 'racetams'.
The primary mechanism of action of Briviact and Keppra involves binding to synaptic vesicle protein 2A (SV2A) in the brain.
The provided BRIVIACT excerpts do not describe mechanism of action or SV2A binding.
By binding to SV2A, Briviact and Keppra are thought to reduce excessive electrical activity that leads to seizures.
The provided BRIVIACT excerpts do not describe SV2A mechanism or reduction of electrical activity.
Briviact has a higher affinity for SV2A than Keppra.
The provided BRIVIACT excerpts do not include affinity comparisons to levetiracetam.
Patients taking Briviact commonly report somnolence.
Label excerpt 5.2 indicates somnolence occurs but does not provide 'commonly' frequency support in the provided text.
Patients taking Briviact commonly report dizziness.
Label excerpt 5.2 includes dizziness but does not provide 'commonly' frequency support in the provided text.
Patients taking Briviact commonly report fatigue.
Label excerpt 5.2 includes fatigue but does not provide 'commonly' frequency support in the provided text.
Patients taking Briviact commonly report behavioral and mood changes such as depression.
The provided excerpts state psychiatric adverse reactions (5.3) but do not specify 'commonly' or list depression specifically.
Patients taking Briviact commonly report behavioral and mood changes such as anxiety.
The provided excerpts state psychiatric adverse reactions (5.3) but do not specify 'commonly' or list anxiety.
Patients taking Briviact commonly report behavioral and mood changes such as irritability.
The provided excerpts state psychiatric adverse reactions (5.3) but do not specify 'commonly' or list irritability.
Keppra's common side effects include somnolence.
No Keppra prescribing information excerpts were provided; also 'common' frequency is not supported by the BRIVIACT excerpt set.
Keppra's common side effects include asthenia (weakness).
No Keppra prescribing information excerpts were provided; not supported by BRIVIACT excerpt set.
Keppra's common side effects include dizziness.
No Keppra prescribing information excerpts were provided; not supported by BRIVIACT excerpt set.
Keppra's common side effects include headache.
No Keppra prescribing information excerpts were provided; not supported by BRIVIACT excerpt set.
Behavioral symptoms including depression, aggression, and psychosis have been reported with Keppra.
No Keppra prescribing information excerpts were provided; not supported by BRIVIACT excerpt set.
Clinical trials have shown Briviact to be effective in reducing seizure frequency.
Section 14 states effectiveness for partial-onset seizures, but the provided excerpts do not include the specific phrase 'reducing seizure frequency' (concept is consistent but exact claim is not directly supported from the provided text excerpts as written).
A study on Briviact indicated a reduction in seizure frequency compared to placebo in adults with partial-onset seizures.
Section 14 supports effectiveness vs placebo but the provided excerpt does not provide the described 'reduction in seizure frequency' wording or 'adults' specific results.
Clinical trials have shown Keppra to be effective in reducing seizure frequency.
No Keppra label excerpts were provided; cannot be evaluated against supplied prescribing information.
Keppra has demonstrated efficacy in clinical trials for adjunctive treatment of partial-onset seizures in children and adults.
No Keppra label excerpts were provided; cannot be evaluated against supplied prescribing information.

Contradictions

Important Omissions

If making a safety claim about driving/operating machinery, the label excerpt specifies advising patients not to drive or operate machinery until sufficient experience (5.2). None of the provided statements mention this required precaution.
Importance: Moderate
If making any suicidality-related safety claims, the label includes a boxed warning on suicidal behavior and ideation for AEDs (5.1). None of the provided statements mention this warning.
Importance: Moderate
If comparing psychiatric adverse reactions, the label states 'BRIVIACT causes psychiatric adverse reactions' (5.3) and monitoring/precautions are not detailed in the provided statements. The statements list specific emotions ('depression/anxiety/irritability') without being supported by the supplied excerpts.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Unknown
Some safety-relevant statements (somnolence/fatigue/dizziness; psychiatric adverse reactions) are directionally consistent with the BRIVIACT label excerpt (5.2 and 5.3) but are not supported with frequency wording ('commonly') and include multiple unsupported Keppra-related claims that cannot be verified from provided BRIVIACT label excerpts.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Multiple claims cannot be evaluated or are unsupported because the provided prescribing information excerpts are for BRIVIACT only, yet the response contains numerous Keppra-specific statements plus mechanism/affinity claims and 'common' frequency assertions not supported by the excerpts.

Suggested Improvement
Restrict evaluation/claims to BRIVIACT and to content explicitly supported by the provided BRIVIACT label excerpts; remove or rephrase Keppra-related statements and avoid asserting 'common/commonly' frequencies or SV2A/affinity details unless supported by the provided label text.

Drug Brand Mention Assessment

Branding Score
65
Visibility
55
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
strong alternative
Brand Perception
Best Known For

Briviact (brivaracetam)

Core Claims
  • Both Briviact and Keppra are antiepileptic drugs used to treat partial-onset seizures.
  • Their primary mechanism of action involves binding to SV2A in the brain.
  • Briviact has a higher affinity for SV2A than Keppra.
  • Clinical trials have shown both Briviact and Keppra to be effective in reducing seizure frequency.
  • The choice between the two often depends on individual patient response, tolerance, and specific seizure characteristics.
Differentiators
  • Briviact has a higher affinity for SV2A than Keppra.
  • Briviact commonly reports behavioral and mood changes such as depression, anxiety, and irritability.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Keppra 45%
55 #2 Yes